Why Antiviral Drug Development Is Harder Than Antibacterial Development
Key Challenges
- Intracellular replication: Viruses hijack host machinery; targeting them risks host toxicity. Bacteria have independent metabolism with unique targets (cell wall, ribosomes, DNA gyrase).
- Mutation rate: RNA viruses mutate 10⁻³–10⁻⁵/base/replication; rapid resistance emergence. Bacteria mutate slower; resistance often requires specific gene acquisition.
- Host specificity: Narrow host range limits market size and clinical trial feasibility. Broad-spectrum antibacterials treat many pathogens.
- Lack of conserved targets: Viral polymerases, proteases vary widely. Bacterial targets (e.g., penicillin-binding proteins) are more conserved across species.
- High evolutionary potential: Quasispecies clouds allow rapid adaptation to selective pressure.
Consequences
- Longer development timelines, higher attrition.
- Need for combination therapy (HAART model) to suppress resistance.
- Continuous surveillance and next-gen drug pipelines essential.
Viral Infections - Related Articles